November 10, 2018 - By Margaret Downey

Abattis Bioceuticals Corp. (OTCMKTS:ATTBF) Logo

The stock of ABATTIS BIOCEUTICALS CORP ORDINARY SHAR (OTCMKTS:ATTBF) registered a decrease of 88.24% in short interest. ATTBF’s total short interest was 19,500 shares in November as published by FINRA. Its down 88.24% from 165,800 shares, reported previously.

The stock decreased 0.52% or $0.001 during the last trading session, reaching $0.095. About 523,266 shares traded. Abattis Bioceuticals Corp. (OTCMKTS:ATTBF) has 0.00% since November 10, 2017 and is . It has underperformed by 15.62% the S&P500.

Abattis Bioceuticals Corp., a biotechnology company, develops, licenses, and markets health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets in Canada. The company has market cap of $40.41 million. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and bioceutical marketing services in the area of health products. It currently has negative earnings. The firm was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corp. in September 2012.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: